AR132479A1 - Nuevas fases sólidas de trimetazidina - Google Patents
Nuevas fases sólidas de trimetazidinaInfo
- Publication number
- AR132479A1 AR132479A1 ARP240101000A ARP240101000A AR132479A1 AR 132479 A1 AR132479 A1 AR 132479A1 AR P240101000 A ARP240101000 A AR P240101000A AR P240101000 A ARP240101000 A AR P240101000A AR 132479 A1 AR132479 A1 AR 132479A1
- Authority
- AR
- Argentina
- Prior art keywords
- trimetazidine
- solid
- pharmaceutically acceptable
- solid phases
- new solid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP23315089 | 2023-04-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR132479A1 true AR132479A1 (es) | 2025-07-02 |
Family
ID=86387194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240101000A AR132479A1 (es) | 2023-04-20 | 2024-04-19 | Nuevas fases sólidas de trimetazidina |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4698157A2 (de) |
| JP (1) | JP2026513056A (de) |
| KR (1) | KR20250169304A (de) |
| CN (1) | CN121079074A (de) |
| AR (1) | AR132479A1 (de) |
| AU (1) | AU2024257489A1 (de) |
| CR (1) | CR20250440A (de) |
| IL (1) | IL324012A (de) |
| MX (1) | MX2025012408A (de) |
| WO (1) | WO2024218267A2 (de) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR805M (de) | 1960-06-30 | 1961-09-01 | ||
| FR2802424B1 (fr) * | 1999-12-17 | 2002-02-15 | Adir | Comprime matriciel permettant la liberation prolongee de trimetazidine apres administration par voie orale |
| FR3027803B1 (fr) | 2014-11-05 | 2018-02-09 | Les Laboratoires Servier | Composition pharmaceutique comprenant un betabloquant et un inhibiteur de l'enzyme de conversion |
| CN110183398B (zh) | 2019-05-14 | 2021-06-29 | 中南民族大学 | 一种曲美他嗪草酸盐及其制备方法和应用 |
| CN110105307B (zh) | 2019-05-14 | 2021-06-01 | 中南民族大学 | 一种曲美他嗪草酸盐及其制备方法和应用 |
| CN110054599B (zh) | 2019-05-14 | 2021-05-07 | 中南民族大学 | 一种曲美他嗪草酸盐及其制备方法和应用 |
-
2024
- 2024-04-19 EP EP24718851.9A patent/EP4698157A2/de active Pending
- 2024-04-19 AR ARP240101000A patent/AR132479A1/es unknown
- 2024-04-19 AU AU2024257489A patent/AU2024257489A1/en active Pending
- 2024-04-19 CR CR20250440A patent/CR20250440A/es unknown
- 2024-04-19 CN CN202480025592.4A patent/CN121079074A/zh active Pending
- 2024-04-19 JP JP2025560230A patent/JP2026513056A/ja active Pending
- 2024-04-19 KR KR1020257038390A patent/KR20250169304A/ko active Pending
- 2024-04-19 WO PCT/EP2024/060657 patent/WO2024218267A2/en not_active Ceased
-
2025
- 2025-10-16 IL IL324012A patent/IL324012A/en unknown
- 2025-10-16 MX MX2025012408A patent/MX2025012408A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2025012408A (es) | 2025-11-03 |
| CN121079074A (zh) | 2025-12-05 |
| WO2024218267A3 (en) | 2024-11-28 |
| KR20250169304A (ko) | 2025-12-02 |
| AU2024257489A1 (en) | 2025-10-30 |
| WO2024218267A2 (en) | 2024-10-24 |
| CR20250440A (es) | 2025-11-25 |
| EP4698157A2 (de) | 2026-02-25 |
| JP2026513056A (ja) | 2026-04-22 |
| IL324012A (en) | 2025-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20210477A1 (es) | Derivado policiclico de carbamoilpiridona | |
| AR043700A1 (es) | Derivados de 3-substituida-4-pirimidona | |
| MX2019009038A (es) | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. | |
| PE20230182A1 (es) | Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter | |
| AR079877A1 (es) | Agonistas peptidicos glp -2 (peptido 2 similar al glucagon) | |
| AR033408A1 (es) | Compuestos de bisarilo que contienen nitrogeno orto, orto-sustituidos, procedimientos para su preparacion, su utilizacion para la preparacion de un medicamento como tambien composiciones farmaceuticas que los contienen | |
| AR029773A1 (es) | Un metodo para inhibir la polimerizacion prematura de monomeros etilenicamente insaturados y una composicion de un monomero etilenicamente insaturado preparada con el mismo | |
| PE20201414A1 (es) | Derivado policiclico de piridona | |
| PE20220252A1 (es) | Compuestos de pirrol | |
| MX2018011721A (es) | Compuesto de griseofulvina. | |
| MX2021007505A (es) | Síntesis de 3-metil-1,2,4-tiadiazol-5-carbohidrazida o de su forma deuterada con metil-d3. | |
| AR127431A1 (es) | Compuestos novedosos | |
| PE20221908A1 (es) | Compuesto triciclico fusionado y su uso farmaceutico | |
| AR125358A1 (es) | Inhibidores heteroaromáticos bicíclicos de la peptidasa 5 relacionada con la calicreína (klk5) | |
| AR126552A1 (es) | Composición farmacéutica para prevenir o tratar la esclerosis sistémica | |
| MX2023011518A (es) | Compuestos heterocíclicos novedosos y sus usos. | |
| PE20242348A1 (es) | Agentes antivirales para el tratamiento y la prevencion de la infeccion por vih | |
| UY25708A1 (es) | Dihidropironas inhibidoras de hiv proteasa | |
| AR107661A1 (es) | Agente terapéutico o profiláctico para la demencia | |
| AR132761A1 (es) | Compuesto inhibidor de la quinasa inducible por sal y composición farmacéutica que lo incluye | |
| AR001785A1 (es) | Composición farmacéutica para la inhibición de producción o secreción de tnf - alfa | |
| MX2023003867A (es) | Combinacion de encorafenib y binimetinib a manera de tratamiento adyuvante contra melanoma resecado en etapa ii. | |
| ES2339632T1 (es) | Composiciones de difluorometano similares a un azeotropo. | |
| CO2025012159A2 (es) | Compuestos inhibidores de la telomerasa | |
| MXPA05013460A (es) | Compuestos de n-{piperazina '4-sustituida-1-sulfonilmetil-alquil}-n-hidroxiformamida como inhibidores de metaloproteinasas. |